| Literature DB >> 35440846 |
Atul K Tiwari1, Anupa Mishra2,3, Govind Pandey4, Munesh K Gupta5, Prem C Pandey1.
Abstract
The COVID-19 infections have posed an unprecedented global health emergency, with nearly three million deaths to date, and have caused substantial economic loss globally. Hence, an urgent exploration of effective and safe diagnostic/therapeutic approaches for minimizing the threat of this highly pathogenic coronavirus infection is needed. As an alternative to conventional diagnosis and antiviral agents, nanomaterials have a great potential to cope with the current or even future health emergency situation with a wide range of applications. Fundamentally, nanomaterials are physically and chemically tunable and can be employed for the next generation nanomaterial-based detection of viral antigens and host antibodies in body fluids as antiviral agents, nanovaccine, suppressant of cytokine storm, nanocarrier for efficient delivery of antiviral drugs at infection site or inside the host cells, and can also be a significant tool for better understanding of the gut microbiome and SARS-CoV-2 interaction. The applicability of nanomaterial-based therapeutic options to cope with the current and possible future pandemic is discussed here.Entities:
Keywords: antiviral drugs; biosensors; drug delivery; nanoformulations; nanotechnology; vaccines
Year: 2021 PMID: 35440846 PMCID: PMC9011707 DOI: 10.1002/ppsc.202100159
Source DB: PubMed Journal: Part Part Syst Charact ISSN: 0934-0866 Impact factor: 3.467
Figure 1Scanning electron microscopic image showing SARS‐CoV‐2(also known as 2019‐nCoV) virus particles (yellow), isolated from a COVID‐19 patient in the U.S., emerging from the surface of host cells (pink) cultured in the lab. Reproduced under terms of the CC‐BY license.[ ] Copyright 2020, NIAID.
Figure 2SARS‐CoV‐2 structure and pathophysiology. A) SARS‐CoV‐2 life cycle: The viral spike (S) protein binds to the ACE2 receptor of the host. Following the entry, the virus envelope's proteolytic cleavage occurs and facilitates the release of viral genomic RNA in the cytoplasm, leading to the formation of small RNAs (subgenomic mRNAs). These mRNAs are translated to several viral proteins (i.e., S, M, N, etc.) essential for the reassembly of the virus particle. These synthesized proteins (S, E, and M) enter the endoplasmic reticulum (ER), where nucleoprotein complex formation occurs from the combination of nucleocapsid (N) protein and genomic positive RNA strand. The complete functional virus particle (proteins and viral genomic RNA assembly) occurs in ER‐Golgi compartments of the host cell. These virus particles are then transported and released via vesicles formation and exocytosis; B) the interaction of ACE2‐RBD (S protein): A single unit of peptidase domain of human ACE2 (red) interacting with the RBD sequence of the virus Spike protein (blue), (boxed region represents the amino acid interactions sites). Reproduced with permission.[ ] Copyright 2020, American Chemical Society.
Figure 3Nanomaterials for prevention and therapy of COVID‐19. Integrating nanomaterials into personal protective equipment (PPE) can prevent the entrance of SARS‐CoV‐2 into the respiratory system. Nanomaterials could also be used as a carrier of drugs to the pulmonary system via inhalators. Cellular interaction of viral particles at the alveoli can be inhibited using targeted NPs against angiotensin‐converting enzyme 2 (ACE2) receptors or viral S protein. Various mechanisms can inactivate viral particles systemically, such as neutralizing NPs or photocatalytic nanomaterials. Nanomaterial‐based vaccines or immunomodulation can prevent SARS‐CoV‐2 infection or even boost the immune response during infection. PDT, photodynamic therapy. Reproduced with permission.[ ] Copyright 2020, American Chemical Society.
Typical antiviral nanoparticles for coating of air filters and protective equipment. PEDV, porcine epidemic diarrhea virus; NDV, Newcastle disease virus
| Nanomaterial types | Size [nm] | Antiviral activity | References |
|---|---|---|---|
| Ag‐NPs | 7.1 | Infected cells treated with Ag‐NPs for 48 h have shown 98% survival |
[
|
| Ag@OTV | 3 | Infected cell survival rate increased to 90% |
[
|
| Ag2S NPs | <5 | Reduces PEDV load more than 99% |
[
|
| Au‐NPs | 10 | Reduce viral load to 92% after 6 h of incubation |
[
|
| CuO NPs | <100 | Viral load reduction reached to five orders of magnitude |
[
|
| Cu2O NPs | 50 | Reduced infection to 90% at concentration of 4 µg mL−1 |
[
|
| TiO2 | 8 | Effective antiviral activity against NDV at the concentration of 6.25 µg mL−1 |
[
|
Advantage and disadvantages of conventional viral detection methodologies
| Detection technique | Detection principle | Detection time | Advantages | Disadvantages | References |
|---|---|---|---|---|---|
| Cell culture | Infectivity assay | Days | Broad spectrum; inexpensive | Difficult to maintain cell cultures; prone to contamination |
[
|
| Electron microscopy | Viral particle | Hours | Broad spectrum; rapid method | minimum 106 particles mL−1 required for detection, prone to cross morphologies |
[
|
| Hemagglutination assay | Viral protein | Hours | Easy; inexpensive | Less sensitive, fresh reagents required |
[
|
| ELISA | Viral protein | Hours | Single step process; effective at high analyte concentrations. | High analyte concentration required, produced antigen or antibody responses are indistinguishable in one step |
[
|
| PCR | Viral nucleic acid | Hours | Extremely high sensitivity; easy to set up | Highly prone to contamination, difficult to quantitate results |
[
|
Figure 5A) Description of operation principle of the Au‐nanoparticle based lateral flow (NPLF) strip. Reproduced with permission.[ ] Copyright 2020, American Chemical Society. B) Schematic presentation of the determination of human IgG based on fluorescence linked immunoassay (FLISA). Reproduced with permission.[ ] Copyright 2020, American Chemical Society.
Quantum dot based nanosensors previously explored for viral infection detection. Hepatitis virus B (HBV); Epstein–Barr virus (EBV)
| Virus | Biosensor type | Interaction site | Labeling site | QDs type | Purpose | References |
|---|---|---|---|---|---|---|
| HBV | Optical | Virus nucleocapsid | RBV | SA‐QDs | Single‐virus tracking |
[
|
| EBV | Optical | Carcinoma cells membrane | Anti‐EBV capsid antigen IgA | CdTe@dBSA‐QDs | Early screening and Diagnosis of EBV‐associated infections |
[
|
| Avian Leukosis Virus (ALVsJ) | electrochemical | Envelope | Anti‐ALV s‐J‐Ab2 | GQD | Viral detection |
[
|
| Influenza Vaxigrip | Electrochemical | Envelope | HA vaxi | CdTe‐QDs | Virus vaccine isolation and detection |
[
|
Figure 4Schematic diagrams are showing different examples of nanomaterial‐based COV detection methods. a) The conjugate of fluorescent Zr QDs and magnetic nanoparticles with antibodies binds specifically to COV. In COV, a magnetic fluorescent complex is formed, isolated magnetically and detected by fluorescence measurements. b) Nanotraps are employed to concentrate COV to improve their stability, and facilitating their detection. c) Reverse transcription PCR (RT‐PCR) is carried out in the presence of nanoparticles, improving the efficacy of the polymerase chain reaction, and resulting in better detection sensitivity of this method. d) COV detection method, which is based on the interactions between complementary DNA originating from COV and acpnPNA probe at the surface of Ag‐NP, results in a separation between Ag‐NPs, and a yellow color associated with the luminescence of well‐dispersed Ag‐NPs, further revealing COV presence. Reproduced with permission.[ ] Copyright 2020, American Chemical Society.
Figure 6A) Viral inhibition using CQDs‐3, CQDs‐5, and CQDs‐6. B) Influence of CQDs, prepared by hydrothermal carbonization, on the binding of HCoV‐229E virus cells: a) inhibition of protein S receptor interaction, and b) inhibition of viral RNA genome replication. Reproduced with permission.[ ] Copyright 2019, American Chemical Society. C) Schematic diagram of diphyllin antiviral mechanism. Diphyllin demonstrated prominent inhibitory activity in anti‐feline infectious peritonitis virus (FIPV) infection by attenuating cellular organelle acidification, thus blocking virus entry. In addition, diphyllin treatment displayed significant suppression in the viral load of Antibody Dependent Enhancement (ADE) of FIPV infections. By using a nanoparticulate drug delivery system, diphyllin exhibited improved safety and enhanced antiviral activity. Reproduced under terms of the CC‐BY licence.[ ] Copyright 2017, The Authors, published by Springer Nature.
Some nanoformulated antiviral nanomaterials and their antiviral mechanism. FCoV, feline coronavirus; PEDV, porcine epidemic diarrhea virus; TGEV, transmissible gastroenteritis virus; PRRSV, porcine reproductive and respiratory syndrome virus; HSV, herpes simplex virus; HV, herpes virus; RSV, respiratory syncytial virus; HAV, hepatitis virus A; MPV, human meta‐peumo‐virus; NA, data not available
| Nanomaterial backbone | Size [nm]/shape | Active nanoagent | Virus type | Results | References |
|---|---|---|---|---|---|
| PEG−PLGA | 40 nm | Diphyllin | F‐CoV | Combination of PEG−PLGA‐diphyllin mediated reduction of endosomal acidification in fcwf‐4 cells |
[
|
| Graphene‐Ag | 7.5 nm | Ag‐NP | F‐CoV | In fcwf‐4 cells, prevents infection of F‐CoV |
[
|
| Ag2S nanoclusters | Sphere 3.2 nm | Ag2S Nanoclusters | PEDV | Reduces PEDV infection in Vero cells by blocking RNA synthesis and budding. |
[
|
| Ag‐NP and NW | <20 nm | Ag NP/NW | TGEV | Reduces TGEV infection in ST cells |
[
|
| Graphene oxide | NA | NA | RSV | Directly bind with virus and block attachment to host cell |
[
|
| Nanogel | NA | NA | PRRSV | Inhibit attachment and penetration. |
[
|
| Ag‐NPs | NA | NA | HV | Inhibit viral attachment |
[
|
| Graphene oxide | NA | NA | HV | Viral attachment inhibitor |
[
|
| Au‐NPs | NA | NA | HV | Inhibition of viral attachment and penetration |
[
|
| Nanocarbon | NA | NA | HV | Inhibit virus entry in cell |
[
|
| Silicon nanoparticles | NA | NA | Influenza A | inhibit progeny virus formation |
[
|
| Gd2O3:Tb3+/Er3+ nanoparticles | NA | NA | Zika virus | Act as antigen carriers for Zk2 peptide of Zika virus |
[
|
| Copper oxide nanoparticles | NA | NA | HSV type 1 | Leads to oxidation of viral proteins and degradation of viral genome |
[
|
| Zirconia nanoparticles | NA | NA | H5N1 influenza virus | Induce cytokines production |
[
|
| Zinc oxide nanoparticles | NA | NA | H1N1 influenza virus | Inhibit virus multiplication |
[
|
| Surface functionalized Antiviral Ag‐NPs | |||||
| Ag‐NPs | Spherical 1−10 nm | Foamy carbon, PVP and BSA | HSV type1 | Interacts with viral protein gp120 |
[
|
| Ag‐NPs | NA | PVP, BSA, and recombinant F protein (RF 412) | RSV | Interacts with G‐protein on the virus surface |
[
|
| Ag‐NPs | Spherical 2−5 nm | Oseltamivir, Amantadine, Zanamivir | H1N1 influenza virus | Block the activity of neuraminidase and hemagglutinin |
[
|
| Ag‐NPs | NA | Poly‐phosphonium‐oligochitosans | HAV, NoV and CoxB4 | Inhibit viral attachment and penetration |
[
|
| Ag‐NPs | Spherical 10−80 nm | Polysaccharide | MPV | Blocking virus‐host cell binding and penetration |
[
|
| Ag‐NPs | Spherical 10 nm | Polysaccharide | TCRV | Inactivates virus outside host cell |
[
|
| Ag‐NPs | Spherical 4 nm | Mercapto‐ethanesulfonate | HSV‐1 | Competitive inhibition of viral binding to the cell |
[
|
| Ag‐NPs | Spherical 2−5 nm | PEI and antiviral siRNA | EV71 | Prevent accumulation of ROS and leads to activation of AKT and p53 proteins |
[
|
| Ag‐NPs | Spherical 46 nm | Tannic acid | HSV‐2 | Blocks the attachment, penetration, and spread of viral particles to the host cell |
[
|
Nanoparticles as immunogenic agents for vaccines. Abbreviations: GM‐CSF, granulocyte−macrophage colony‐stimulating factor; HA, hemagglutinin; iBALT, inducible bronchus‐associated lymphoid tissue; PLGA, poly (lactic‐co‐glycolic acid); STING, stimulator of interferon genes
| NPs | Conjugate/adjuvant | Size [nm] | Virus | Model organism | Outcomes | References |
|---|---|---|---|---|---|---|
| Au‐NPs | SARS‐CoV Spike protein | 40, 100 | SARS | In vivo; BALB/c mice | Strongly induce IgG response |
[
|
| VLPs with Au‐NPs | Avian IBV Spike protein |
AuNPs:100 VLPs:139 | IBV | In vivo; BALB/c mice | Induce strong antigen‐specific cellular immunity, IgG, IgA responses. |
[
|
| VLPs from MERS CoV Spike protein |
Alum, matrix M1 | NA | MERS | In vivo; BALB/c mice | VLPs and Matrix M1 induce high anti‐S titers |
[
|
| VLPs from SARS CoV and MERS‐CoV Spike protein |
Alum, matrix M1 | ≈25 | SARS, MERS | In vivo; BALB/c mice | Induce high antibody titers against homologous virus. |
[
|
| VLPs from MERS‐CoV Spike protein | Ad5/MERS, Alum |
VLPs: 35 with alum: 80 | MERS | In vivo; BALB/c mice | Induces CD8+ T cell, TNF‐α, IL‐2, GM‐CSF, and IFN‐c responses. |
[
|
| VLPs from HRC subunit of SARS‐CoV Spike protein | 25−30 | SARS | In vivo; BALB/c mice | Generate neutralizing mice antisera |
[
| |
| VLPs from bacteriophage P22 | IAV HAs | ≈26 | SARS, Influenza A | In vivo; C57BL/6 mice | Recognizable by TLR‐2 receptor and protect from infection and weight loss |
[
|
| VLPs using canine parvovirus | MERS‐CoV RBD, poly(I:C) | ≈25 | MERS | In vivo; BALB/c mice | Mixed Th1 and Th2 responses, increase in antibody titers |
[
|
| Chitosan NPs | SARS‐CoV N protein | 210 ± 60 | SARS | In vivo; BALB/c mice | Dendritic cell targeting, strong CD4+ response, high levels of IgG, IgG1, IgG2a, IgG2b, IgA, IFN‐γ |
[
|
| Heat shock protein caged NPs | NA | 120 | SARS, H1N1, RSV | In vivo; C57BL/6 |
Induce strong nasal antibodies. formation of iBALT structures of B cells, CD4+ T cells, dendritic cells and CD8+ T cells. |
[
|
| PLGA | STING, MERS‐CoV Spike protein, MF59 | ≈148 | MERS | In vivo; C57BL/6 mice |
STING encapsulated in PLGA induce strong RBD specific CD4+, CD8+, balanced Th1/Th2 response. IgG2a; IFN‐β, TNF‐α, IL6 generation |
[
|
| CDs | NA | 1.6 | PEDV | In vitro; Vero and PK‐15 cells | Induce IFNs and pro‐inflammatory cytokines |
[
|
Summary of nanomaterial‐based approaches for the improvement of physiochemical properties of photosensitizers (PSs)
| Approach | Chemical moiety | Action mechanism | Physicochemical characteristics | References |
|---|---|---|---|---|
| Development of advanced PSs with unique physicochemical properties | Organic derivatives of conventional PSs, nanoparticle‐based organic dyes | Intramolecular or intermolecular resonance energy transfer | Highly biocompatible, involved in type II PDT and less Stable |
[
|
| Inorganic semiconductors such as TiO2, β‐SnWO4, G‐QDs, bismuth oxyhalide, and Cd‐Se | Separation of electrons holes from the covalent band and conduction band | Highly stable, tunable optical properties, involved in type I and type II PDT |
[
| |
| On the basis of utilization of different lights | NIR‐activated nanomaterials such as UCNP‐based Nanoplatforms and TPA | FRET from photoconverting or self‐illuminating nanoparticles to PSs | Deep tissue penetration capability and have potential photothermal effect |
[
|
| X‐ray‐activated nanomaterial materials such as SCNPs, PLNPs | Deep tissue penetration capability, can lead to potential radiation damage |
[
| ||
| Design of new platforms based on the features of TME | TME‐responsive nanomaterials: biochemical‐triggered PDT enhancement | Mutual interactions between nanomedicines and TME to favor tumors targeting | High selectivity, specificity, efficiency, and bioavailability |
[
|
| TME‐modulating nanomaterials: reoxygenation in hypoxic tumors | Decomposition of hyperoxide or water to generate O2 and relieve hypoxia | Low oxygen dependence and enhanced ROS‐generating efficiency |
[
|
Figure 7A) Band‐structure characterization and photocatalytic disinfection mechanism of ZIF‐8 (zinc‐imidazolate MOF). i) The band positions of ZIF‐8 for the reactive oxygen species (ROS) formation potential, conduction band (CB), and valence band (VB) represent conduction band and valence band, respectively. ii) Electron paramagnetic resonance (EPR) spectra of ZIF‐8 at 77 K in dark and under light irradiation (300 nm < λ < 1100 nm) in different atmosphere. iii) EPR spectra of DMPO−•O2− for ZIF‐8 under light irradiation and in the dark. iv) Steady‐state concentration of •O2− calculated from the decay of nitroblue tetrazolium (NBT) and hydrogen peroxide (H2O2) accumulation over time, respectively. v) The first‐order disinfection rate on ZIF‐8 with different scavengers (IPA → •OH, L‐His → 1O2, Cr (VI) → e−, Oxalate → h+, SOD → •O2−, CAT → H2O2). vi) Dependence of the amount of released H2O2 by ZIF‐8 on the wavelength of incident light and the ultraviolet–visible (UV–vis) spectra of ZIF‐8. The error bars are calculated by repeating the measurements three times. SOD superoxide dismutase, IPA isopropanol, DMPO 5,5‐diemthyl‐1‐pyrroline N‐oxide. B) Schematic of metal–organic framework (MOF)‐based filter. Schematic representation of MOF‐based filter (MO‐filter) for integrated air cleaning. Reproduced with permission under common creative 4.0 attribution licence.[ ] Copyright 2019, The Author(s).
Figure 8A) Different nanocarrier platforms utilized for combination drug therapeutics. Reproduced with permission[ ] Copyright 2020, ACS nano. B) Schematic of ML336 loaded LC‐MSNs. The antiviral ML336 was incubated with MSNs before vesicle fusion with liposomes containing a composition of 77.5% DSPC:2.5% DSPE‐PEG 2000:20% cholesterol at mole ratios; Reproduced with permission.[ ] Copyright 2018, Springer Nature. C) An illustration of an active nanosystem demonstrating antimicrobial peptide delivery into an infected cell. Reproduced with permission under common creative attribution licence.[ ] Copyright 2018, The Author(s).
Categories of nanomaterials used for nanoformulated drug/vaccine delivery
| Type of materials | Classical example | Functions/Advantages | References |
|---|---|---|---|
| Organic nanoparticle‐based carriers | Liposomes | The efficient and controlled delivery of nucleic acid‐based antigens |
[
|
| Polymer‐based nanoparticle | Efficient loading of different cargos with various forms and functions; shows self‐adjuvanticity in some cases |
[
| |
| Inorganic nanoparticle‐based carriers | Mesoporous silica nanoparticles | Multiple site cargo loading; controllable release of cargo; shown self‐adjuvanticity in some cases |
[
|
| Magnetic nanoparticles | Vaccine delivery along with imaging capabilities |
[
| |
| Gold nanoparticles | Vaccine delivery along with imaging capabilities |
[
|